EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association of Liver Fibrosis-4 Index with Adverse Outcomes in Hypertrophic Cardiomyopathy Patients

Fuad A Abdu, Redhwan M Mareai, Lanqing Xiang, Jassur Galip, Abdul-Quddus Mohammed, Wen Zhang, Lu Liu, Chunyue Wang, Ayman A Mohammed, Guoqing Yin, Xian Lv, Yawei Xu und 1 weitere

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Fuad A Abdu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Liver Cirrhosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chinese National Natural Science Foundation, Shanghai Natural Science Foundation of China, Foundation of Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The fibrosis-4 index (FIB-4) is a non-invasive tool to assess fibrosis risk in chronic liver disease. We aimed to explore the relationship between the FIB-4 index and long-term major adverse cardiovascular events (MACE) in HCM patients. Methods and results Consecutive patients diagnosed with HCM were included. Patients were divided into two groups using a defined cutoff value established through a ROC analysis for predicting MACE (FIB-4 ≥ 2.37 and FIB-4 < 2.37). The final analysis comprised 187 HCM patients (34.8% females, 66.49 ± 11.43 years of age), with 47 (25.1%) in the FIB-4 ≥ 2.37 group and 140 (74.9%) in the FIB-4 < 2.37 group. Among these, 147 (78.6%) individuals had complete follow-up data. Patients with FIB-4 ≥ 2.37 demonstrated a higher prevalence of co-morbidities such as atrial fibrillation (27.7% vs. 7.9%; P < 0.001), heart failure (55.3% vs. 24.3%; P < 0.001), elevated NT-proBNP levels (3.03 ± 4.74 vs. 0.66 ± 1.08; P < 0.001), and lower LVEF (58.51 ± 7.86 vs. 61.84 ± 5.04; P = 0.001). Over a median of 41 (IQR 16–63) months follow-up, MACE occurred in 49 (33.3%), with a significantly higher incidence in the FIB-4 ≥ 2.37 group (58.8% vs. 25.7%, P < 0.001). Cardiac death rates were also elevated in the FIB-4 ≥ 2.37 group (20.6% vs. 2.7%, P = 0.001). Cox regression analysis revealed an independent association between FIB-4 ≥ 2.37 and a higher risk of MACE (adjusted HR: 1.919, 95% CI 1.015–3.630; P = 0.045) and cardiac death (adjusted HR: 9.518, 95% CI 1.718–52.732; P = 0.010). Furthermore, the FIB-4 index shows positive correlations with left atrium diameter (r = 0.229; P = 0.003), septal thickness (r = 0.231; P = 0.002), posterior wall thickness (r = 0.235; P = 0.001), and NT-proBNP (r = 0.271; P < 0.001). Conversely, a negative correlation was observed between the FIB-4 index and left ventricular ejection fraction (r = −0.185; P = 0.011).

Conclusion

Elevated FIB-4 index, indicative of liver fibrosis, is independently associated with an increased risk of long-term MACE in HCM patients. This emphasizes the potential influence of liver function abnormalities on HCM prognosis, underscoring the need for comprehensive risk assessment in clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicLiver CirrhosisHumansFemaleMaleAgedFollow-Up StudiesPrognosisRetrospective StudiesMiddle AgedRisk AssessmentSurvival RateRisk Factors

Stichwörter der Autor:innen

Fibrosis‐4 indexHypertrophic cardiomyopathyLiver fibrosisPrognosis

Autor:innen und Institutionen

  • Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of Cardiology, Shanghai Tenth People's Hospital Chongming branch, Shanghai, China.

Förderung

  • Chinese National Natural Science Foundation
  • Shanghai Natural Science Foundation of China
  • Foundation of Shanghai Municipal Health Commission
  • Tibet Natural Science Foundation of China
  • Foundation of Chongming
  • Clinical Research Plan of Shanghai Tenth People's Hospital
  • Clinical Research Plan of SHDC
  • Foundation of the Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Abdu, F. A., Mareai, R. M., Xiang, L., Galip, J., Mohammed, A. Q., Zhang, W., Liu, L., Wang, C., Mohammed, A. A., Yin, G., Lv, X., Xu, Y., & Che, W. (2024). Association of Liver Fibrosis-4 Index with Adverse Outcomes in Hypertrophic Cardiomyopathy Patients. ESC Heart Failure. https://doi.org/10.1002/ehf2.14977

Vancouver

Abdu FA, Mareai RM, Xiang L, Galip J, Mohammed AQ, Zhang W, et al. Association of Liver Fibrosis-4 Index with Adverse Outcomes in Hypertrophic Cardiomyopathy Patients. ESC Heart Failure. 2024. doi:10.1002/ehf2.14977

BibTeX
@article{Abdu2024,
  author = {Abdu, Fuad A and Mareai, Redhwan M and Xiang, Lanqing and Galip, Jassur and Mohammed, Abdul-Quddus and Zhang, Wen and Liu, Lu and Wang, Chunyue and Mohammed, Ayman A and Yin, Guoqing and Lv, Xian and Xu, Yawei and Che, Wenliang},
  title = {Association of Liver Fibrosis-4 Index with Adverse Outcomes in Hypertrophic Cardiomyopathy Patients},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14977}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche